Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients.
Mult Scler Relat Disord. 2019 May; 30:247-251.MS

Abstract

BACKGROUND

Efficacy and safety profiles of alemtuzumab for relapsing-remitting multiple sclerosis (RRMS) mainly come from Western countries and have not been reported in Asian populations. The aim of this study was to report the efficacy and safety of alemtuzumab for RRMS patients in a Korean population.

METHODS

We retrospectively reviewed RRMS patients treated with alemtuzumab. Study outcomes included annualized relapse rate (ARR), expanded disability status scale (EDSS) score, 6-month confirmed disability worsening (CDW), confirmed disability improvement (CDI), MRI lesion activity (new/enlarging T2 hyperintense and gadolinium-enhancing T1 lesions), no evidence of disease activity (NEDA), and adverse events.

RESULTS

Nineteen patients were identified and mean follow-up was 1.5 years after alemtuzumab initiation. Mean ARR fell from 1.20 pre-treatment to 0.30 post-treatment (p < 0.001). Mean EDSS score remained stable, with a change from baseline of -0.08 at 1 year. After treatment, 16 patients (84.2%) had freedom from 6-month CDW, 3 (15.8%) had 6-month CDI, 11 (57.9%) had freedom from new/enlarging T2 hyperintense lesions, 13 (68.4%) had freedom from gadolinium-enhancing lesions, and 10 (52.6%) had NEDA. Four patients (21.1%) developed relapses after alemtuzumab therapy.

CONCLUSION

Alemtuzumab efficacy and safety were similar to that reported previously in Western populations. Severe relapses can occur after alemtuzumab administration.

Authors+Show Affiliations

Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea. Electronic address: limy@amc.seoul.kr.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30849681

Citation

Kim, Hyunjin, et al. "Efficacy and Safety of Alemtuzumab in Korean Multiple Sclerosis Patients." Multiple Sclerosis and Related Disorders, vol. 30, 2019, pp. 247-251.
Kim H, Lee EJ, Kim SK, et al. Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients. Mult Scler Relat Disord. 2019;30:247-251.
Kim, H., Lee, E. J., Kim, S. K., Kim, K. K., & Lim, Y. M. (2019). Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 30, 247-251. https://doi.org/10.1016/j.msard.2019.03.001
Kim H, et al. Efficacy and Safety of Alemtuzumab in Korean Multiple Sclerosis Patients. Mult Scler Relat Disord. 2019;30:247-251. PubMed PMID: 30849681.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients. AU - Kim,Hyunjin, AU - Lee,Eun-Jae, AU - Kim,Sung Keun, AU - Kim,Kwang-Kuk, AU - Lim,Young-Min, Y1 - 2019/03/02/ PY - 2018/10/30/received PY - 2019/01/08/revised PY - 2019/03/01/accepted PY - 2019/3/9/pubmed PY - 2019/8/10/medline PY - 2019/3/9/entrez KW - Alemtuzumab KW - Efficacy KW - Korean KW - Multiple sclerosis KW - Safety SP - 247 EP - 251 JF - Multiple sclerosis and related disorders JO - Mult Scler Relat Disord VL - 30 N2 - BACKGROUND: Efficacy and safety profiles of alemtuzumab for relapsing-remitting multiple sclerosis (RRMS) mainly come from Western countries and have not been reported in Asian populations. The aim of this study was to report the efficacy and safety of alemtuzumab for RRMS patients in a Korean population. METHODS: We retrospectively reviewed RRMS patients treated with alemtuzumab. Study outcomes included annualized relapse rate (ARR), expanded disability status scale (EDSS) score, 6-month confirmed disability worsening (CDW), confirmed disability improvement (CDI), MRI lesion activity (new/enlarging T2 hyperintense and gadolinium-enhancing T1 lesions), no evidence of disease activity (NEDA), and adverse events. RESULTS: Nineteen patients were identified and mean follow-up was 1.5 years after alemtuzumab initiation. Mean ARR fell from 1.20 pre-treatment to 0.30 post-treatment (p < 0.001). Mean EDSS score remained stable, with a change from baseline of -0.08 at 1 year. After treatment, 16 patients (84.2%) had freedom from 6-month CDW, 3 (15.8%) had 6-month CDI, 11 (57.9%) had freedom from new/enlarging T2 hyperintense lesions, 13 (68.4%) had freedom from gadolinium-enhancing lesions, and 10 (52.6%) had NEDA. Four patients (21.1%) developed relapses after alemtuzumab therapy. CONCLUSION: Alemtuzumab efficacy and safety were similar to that reported previously in Western populations. Severe relapses can occur after alemtuzumab administration. SN - 2211-0356 UR - https://www.unboundmedicine.com/medline/citation/30849681/Efficacy_and_safety_of_alemtuzumab_in_Korean_multiple_sclerosis_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2211-0348(19)30106-3 DB - PRIME DP - Unbound Medicine ER -